The FDA advisory panel rejected MDMA-assisted therapy for PTSD due to concerns about study designs, participants' ability to guess MDMA use, and potential biases. [ more ]
The FDA advisory panel rejected MDMA-assisted therapy for PTSD due to concerns about study designs, participants' ability to guess MDMA use, and potential biases. [ more ]